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Synopsis
The autosomal dominantly inherited disease AIP (acute intermittent porphyria) is caused by mutations in HMBS
[hydroxymethylbilane synthase; also known as PBG (porphobilinogen) deaminase], the third enzyme in the haem
biosynthesis pathway. Enzyme-intermediates with increasing number of PBG molecules are formed during the catalysis
of HMBS. In this work, we studied the two uncharacterized mutants K132N and V215E comparative with wt (wild-
type) HMBS and to the previously reported AIP-associated mutants R116W, R167W and R173W. These mainly
present defects in conformational stability (R116W), enzyme kinetics (R167W) or both (R173W). A combination
of native PAGE, CD, DSF (differential scanning fluorimetry) and ion-exchange chromatography was used to study
conformational stability and activity of the recombinant enzymes. We also investigated the distribution of intermediates
corresponding to specific elongation stages. It is well known that the thermostability of HMBS increases when the
DPM (dipyrromethane) cofactor binds to the apoenzyme and the holoenzyme is formed. Interestingly, a decrease in
thermal stability was measured concomitant to elongation of the pyrrole chain, indicating a loosening of the structure
prior to product release. No conformational or kinetic defect was observed for the K132N mutant, whereas V215E
presented lower conformational stability and probably a perturbed elongation process. This is in accordance with the
high association of V215E with AIP. Our results contribute to interpret the molecular mechanisms for dysfunction of
HMBS mutants and to establish genotype–phenotype relations for AIP.
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INTRODUCTION
The porphyrias are a group of rare metabolic disorders caused
by malfunction of the enzymes in the haem biosynthesis
pathway. Mutations in the third enzyme of this synthesis,
HMBS [hydroxymethylbilane synthase; also known as PBG
(porphobilinogen) deaminase, EC 2.5.1.61] are associated with
the most frequently occurring acute porphyria, AIP (acute
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intermittent porphyria), an autosomal dominant inherited
disease. Increased demand for haem, and thus an up-regulation
of the haem biosynthesis, is induced by hormonal, environ-
mental and metabolic factors among others. With deficient
HMBS activity, an up-regulated haem biosynthesis results in
accumulation of the haem precursors ALA (δ-aminolaevulinic
acid) and PBG in tissues, which may trigger acute attacks
(for reviews, see [1,2]). To date, more than 385 different
mutations in the HMBS gene have been reported (available at
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http://www.hgmd.cf.ac.uk/ac/gene.php?gene = HMBS). Loss
of important salt bridges or other intramolecular interactions
because of mutations can lead to different effects on enzyme
kinetics, stability, flexibility and dynamics of the enzyme. In
this work, two uncharacterized Norwegian mutants, K132N
and V215E, are compared with wt (wild-type) HMBS and the
previously reported AIP-associated mutants R116W, R167W
and R173W, which present defects mainly in conformational
stability (R116W), enzyme kinetics (R167W) or both (R173W).
See Supplementary Figure S1 (at http://www.bioscirep.org/bsr/
033/bsr033e056add.htm) for a structural model and localization
of the mutants.
Two HMBS isoforms have been reported in humans [3]; a
housekeeping enzyme, referred to as HMBS (361 amino acids;
Mw 39 330), which is ubiquitously expressed and active in all tis-
sues, and an erythroid form [eHMBS (erythroid hydroxymethylb-
ilane synthase), 344 amino acids; Mw 37 699] lacking 17 residues
in the N-terminal. There seems to be no differences in Vmax or
Km between the two isoforms [4]. The available crystal struc-
ture of human HMBS is valuable as a starting point to interpret
the pathogenic mechanism for AIP-associated HMBS mutations
[5,6] (PDB ID 3ECR), but it has not provided information on
the 17 N-terminal residues that differ between the isoforms. The
monomeric enzyme is organized in three domains (Supplement-
ary Figure S1). Domain 1 (residues 1–116 and 216–239) and
domain 2 (residues 117–215) are connected by a hinge region
that introduce flexibility, whereas the hydrophobic cleft that is
formed between the two domains defines the active site. Do-
main 3 (C-terminus, residues 240–361) holds a loop containing a
conserved cysteine (Cys261) to which the DPM (dipyrromethane)
cofactor binds covalently.
HMBS is thought to be expressed as an apoenzyme with a
unique ability to assemble its own cofactor. The enzyme cata-
lyses the assembly of four PBG molecules into the linear pre-
cursor of uroporphyrinogen III, HMB (hydroxymethylbilane,
also called preuroporphyrinogen). Four enzyme–intermediate
complexes emerge during this process (for a review, see [7]).
The first three complexes (ES, ES2 and ES3) are relatively stable,
whereas the fourth complex, ES4, is quickly hydrolysed into
HMB [8]. The cofactor itself is not turned over and HMBS
leaves the reaction as a holoenzyme [8,9]. The catalytic process of
HMBS has been extensively studied [8,10–12], but the mechan-
ism is still not fully understood. Several salt bridges and hydrogen
bonds are established when the cofactor binds to HMBS, indu-
cing additional interactions within the enzyme and cross-linking
the domains [5,6,13]. These interactions lead to a stable struc-
ture that is resistant to both heat treatment and urea denaturation
[14–16]. However, the subsequent condensation of the four PBG
molecules is thought to induce conformational changes leading
to an opening of the enzyme, giving space for the tetrapyrrole
[6,12,13].
In this work, we aimed to further characterize malfunctioning
mechanisms of HMBS mutants, and selected four natural muta-
tions found in Norwegian AIP patients (R116W, R167W, R173W
and V215E). In addition, K132N, detected in a patient presented
with abdominal pain and indistinct porphyria-related biochem-
ical findings, was included. We studied the conformational and
thermal stability of recombinant wt HMBS and the five selected
mutants. K132N, carrying a mutation located on the surface, far
from the active site, has to our knowledge not previously been
reported. V215E, although reported [17], has not been character-
ized. V215E is located in the hinge region between domains 1
and 2, close to the active site and is one of the most common AIP
mutations in Norway. 59 % of patients with this mutation exper-
ience porphyria attacks. The results of the novel mutants were
validated by comparative analyses with the already characterized
mutants R116W [15,18], R167W [19–21] and R173W [21–24].
These three mutations were chosen because of their different ef-
fects on the activity and conformational stability of HMBS. The
kinetic failure of R116W can be associated with a strong con-
formational defect causing a severely misfolded enzyme unable
to acquire the cofactor [5,25]. The misfolded R173W mutation
has also been shown to be catalytically deleterious, and it is
assumed that the substitution of the arginine residue will lead
to an improper binding of cofactor and substrate, resulting in
blocking of catalysis [23,26]. Furthermore, R167W is a cata-
lytic mutant expected to have an inefficient elongation process,
that consequently accumulates enzyme–intermediate complexes
[6,27,28].
By using a combination of methods including native PAGE,
enzyme kinetics, CD, DSF (differential scanning fluorimetry)
and ion-exchange chromatography, we provide the comparative
results on the wt HMBS and selected mutants that contribute
to a better understanding of the elongation mechanism and the
molecular basis of the dysfunctions of AIP associated mutations.
R116W and R173W, which are the two mutants with the most
severe phenotype, also present an almost total kinetic dysfunction
that is largely related to their severe conformational instability.
For the mutants R167W and V215E, which present a less severe
phenotype, but yet a high association with AIP, the clinical profile
appears to be related to a kinetic and a conformational instability,
respectively. For K132N, no defect in enzyme kinetics, conform-
ation or stability could be shown, which seems to fit with the lack
of a clear phenotypic association with AIP for this mutant.
EXPERIMENTAL
Patients
Of all known porphyria patients in Norway, 70 % are registered
in the NPR (Norwegian Porphyria Registry) administered by the
NAPOS (Norwegian Porphyria Centre). The register holds pa-
tients who have experienced symptoms or attacks because of
their porphyria (designated active) as well as patients with latent
porphyria who have never had symptoms that could be attributed
to porphyria (mostly relatives of patients predictively examined
by DNA sequence analysis). Each patient answers a disease-
specific questionnaire, and information on diagnosis, symptoms,
biochemical and genetic characteristics, is recorded. A total of
680 patients with AIP, all heterozygote, are registered in the NPR.
Of these, 18 (15 active) have the R116W mutation, four patients
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Acute intermittent porphyria-associated mutations
(three active) are registered with R167W and another four (three
active) with the R173W mutation. V215E is registered with 37 (22
active) patients in the NPR. The mutation K132N was discovered
in a patient where sequencing of the HMBS gene was performed
on the basis of abdominal pain and unclear porphyria-related bio-
chemical findings. Following further biochemical studies, neither
the index K132N patient nor the nine family members confirmed
to have the Lys→Asn substitution have at any time presented
biochemical findings consistent with a diagnosis of AIP.
Biochemical diagnosis of AIP was performed at the Laborat-
ory of Clinical Biochemistry, HUS (Haukeland University Hos-
pital). AIP has been established on the basis of increased u-
ALA (urinary ALA) and u-PBG (urinary PBG) measured by
ion-exchange chromatography [29] in relation to creatinine, and
by reduced eHMBS activity measured in washed erythrocytes as
described by Ford et al. [30]. DNA analyses were carried out at
the Centre for Medical Genetics and Molecular Medicine, HUS.
The study was approved by the Regional Committee for Med-
ical Research Ethics, and informed consent was gathered from
all patients.
Site-directed mutagenesis
The plasmid for protein expression of human HMBS was gener-
ously provided by Professor Pavel Martasek and Dana Ulbrichova
as pGEX4T-1-expression vector [31]. The missense mutations
R116W, K132N, R167W, R173W and V215E were introduced
into HMBS cDNA using QuikChange® lightning mutagenesis
kit (Stratagene). To verify the mutations, the entire gene was
sequenced.
Expression and purification of HMBS proteins
Wt and mutant HMBS were expressed in Escherichia coli BL21
(DE3) pLysS (Stratagene) as glutathione S-transferase fusion pro-
teins. After inoculation with 50 ml overnight pre-cultures the
cells were grown at 37 ◦C in 950 ml Luria Bertani broth sup-
plemented with 100 μM ampicillin, 34 μg/ml chloramphenicol
and 2 g/l glucose. At A600∼0.8 protein expression was induced by
1 mM IPTG (isopropyl thio-β-D-galactoside), grown overnight at
28 ◦C, and harvested by centrifugation at 4 ◦C, 4000 g for 15 min.
Washed cells were subsequently resuspended in PBS (140 mM
NaCl, 2.7 mM KCl, 10 mM Na2HPO4 and 1.8 mM KH2PO4), pH
7.4, containing 1 mM EDTA, 0.5 mM PMSF, 1 mM benzamidine
and protease inhibitor (cOmplete ULTRA tablet, Roche Applied
Science), and sonicated on ice. The sonicate was centrifuged at
14 000 g for 45 min at 4 ◦C, before the supernatant was loaded
onto a glutathione-sepharose 4B column (GE Healthcare), and
washed with 500 ml PBS containing 1 mM EDTA, followed by
two column volumes of only PBS. The thrombin (200 units/l)
digest was performed by gently shaking at 4 ◦C for 2 h in 50 mM
Tris–HCl, pH 8.0, containing 2 mM CaCl2, 1 mM DTT (dith-
iothreitol) and 150 mM NaCl. The final purified proteins, in
50 mM Tris–HCl, pH 8.0, were up-concentrated (>10 mg/ml)
with 30 kDa cut-off filters (Amicon Ultra centrifugal filters, Mil-
lipore), aliquoted and stored in liquid N2 until use. The purity of
the protein was confirmed by SDS–PAGE.
Enzymatic activity assay of recombinant HMBS
The enzymatic activity of recombinant HMBS was assayed in
50 mM Na-Hepes, pH 8.2, containing 0.1 M DTT. Approx. 5 μg
enzyme was pre-incubated for 3 min at 37 ◦C and the enzyme
reaction was initiated by the addition of 100 μM preheated PBG
solution. After 4 min the reaction was terminated by the addition
of 5 M HCl and benzoquinone (0.1 % in methanol) and samples
were incubated on ice for 30 min, protected from light, before the
absorbance was determined at 405 nm. The activity of recombin-
ant HMBS was defined as nmol of uroporphyrinogen I/h per
mg of enzyme at 37 ◦C under the given assay conditions. Km and
Vmax were determined using varying PBG concentrations ranging
from 1.5 μM to 4 mM. Protein concentrations were determined
from the theoretical molar extinction coefficients (ε280 = 0.39 for
wt, V215E and K132N, and ε280 = 0.54 for R116W, R167W and
R173W, for a 0.1 % solution) [32]. The kinetic parameters were
obtained by non-linear curve fitting using Sigma Plot 11.0 with
the additional module EKWizard 1.2.0.0.
Anion-exchange chromatography
The enzyme (∼1 mg of wt or ∼3 mg of V215E) was applied
to a MiniQ 4.6/50 PE column (GE Healthcare) equilibrated in
50 mM Tris–HCl, pH 8.2 at 4 ◦C, attached to a Bio-Rad Biologic
Duo Flow FPLC system. Elution was performed using a pre-
programmed NaCl gradient (0–400 mM NaCl) with collection of
200 μl fractions, and the absorbance was monitored at 280 nm.
The individual peaks were collected and up-concentrated using
Amicon Ultra 30 kDa cut-off centrifugal filters (Millipore) for
further analysis by DSF.
Polyacrylamide gel electrophoresis
10 % (w/v) SDS- and native PAGE were both performed in a
discontinuous system (stacking gel buffer pH 6.8 and running
gel buffer pH 8.8) with Tris–glycine tank buffer (pH 8.3) at room
temperature (22 ◦C) [33]. Native PAGE was performed without
denaturing agents (SDS, 2-mercaptoethanol) and samples were
not heated prior to loading [16]. Approx. 5 and 10 μg enzyme
were applied for SDS–PAGE and native PAGE, respectively.
Circular dichroism
A Jasco J-810 spectropolarimeter equipped with a PTC-348WI
Peltier element for temperature control at 25 ◦C and a 300 μl
quartz cell with a path length of 1 mm were used for far-
UV and thermal denaturation CD measurements. The HMBS
samples (final concentrations 5–9 μM) were prepared in 10 mM
K-phosphate, pH 8.2, 150 mM KF. Four scans were accumulated
for each spectrum and buffer scans were subtracted, using the ac-
companying software from Jasco. Thermal denaturation profiles
were obtained by recording the ellipticity at 222 nm as a function
of temperature between 20 and 95 ◦C (2 ◦C/min). The far-UV
and thermal scans were smoothed using a negative exponential
algorithm with a sample proportion = 0.05 and polynomial de-
gree = 2 (1 for thermal scans). CDNN [34] was used to estimate
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Table 1 eHMBS activity, and u-ALA and u-PBG concentrations in AIP patients with the selected HMBS mutations, compared with
healthy individuals
eHMBS (units/l)* u-ALA/creatinine (μmol/mmol) u-PBG/creatinine (μmol/mmol)
Mutation No. of patients (number active) Range Mean Range Mean Range Mean
Healthy† - 0.43–0.89 - <5.0 - <0.8 -
R116W 18 (15) 0.20–0.41 0.29 1.52–78.39 10.48 0.33–46.05 12.31
K132N 10 (0) 0.32–0.61 0.46 2.08–5.99 2.93 0.32–0.54 0.43
R167W 4 (3) 0.28–0.42 0.36 2.41–8.21 5.62 0.35–8.47 5.39
R173W 4 (3) 0.19–0.27 0.24 1.85–3.27 2.60 0.40–1.21 0.92
V215E 37 (22) 0.16–0.61 0.32 1.20–19.02 5.18 0.31–33.89 5.67
*One unit of HMBS activity is 1 μmol of uroporphyrinogen I/min.
†Reference values compiled at HUS.
the secondary structure content. The thermal scans were normal-
ized and curve fitted to a two-state unfolding model [35] and
converted to fraction of unfolded protein [36]. The slope was
fixed to zero (md = 0) for post-transitional baseline.
Differential scanning fluorimetry
A LightCycler 480 Real-Time PCR System (Roche Applied Sci-
ence) was used for the fluorimetric thermal denaturation scans.
50 μl of either 2.5 μM HMBS or mutants in 10 mM K-phosphate,
pH 8.2, 150 mM KF and 5× SYPRO Orange (Molecular Probes,
Inc.) were added to each well of a 96-well plate (Roche Applied
Science). The plates were incubated for 30 min at room tem-
perature prior to thermal scans. The increase in SYPRO Orange
fluorescence is associated with protein unfolding (λex = 465 nm,
λem = 610 nm) and was used for monitoring the thermal denatura-
tion. The thermal scans were performed at a scan rate of 2 ◦C/min
from 20 to 95 ◦C with data points collected approximately every
0.2 ◦C. The data were scaled to reflect the fraction of unfolded
protein. Tm (half-denaturing temperature)-values were determ-
ined at fraction of unfolded = 0.5, as well as from the maxima of
the first derivative.
Titration experiments by DSF were performed under identical
conditions as above, except that 1, 25, 50 or 100 μM PBG was
added to wt or mutants. R167W was additionally titrated with
500 and 1000 μM PBG.
RESULTS AND DISCUSSION
Patient data
The mean values of eHMBS activity, u-ALA and u-PBG were
within the reference limits for the patients with the K132N muta-
tion. The mean levels of eHMBS activity for the other four muta-
tions were all below the lower reference limit. The results are
summarized in Table 1. The analyses indicate a very severe phen-
otype for the patients with the R116W and R173W mutations,
and severe for R167W and V215E. The biochemical analyses did
not reveal any effect of the K132N mutation on the biochemical
phenotype.
Figure 1 SDS–PAGE and native PAGE of wt and mutant HMBS
(A) SDS–PAGE showing recombinant HMBS as purified: Wt (lane 1),
R116W (lane 2), K132N (lane 3), R167W (lane 4), R173W (lane 5) and
V215E (lane 6). Low molecular mass SDS–PAGE standards (lane 7).
(B) Native PAGE of recombinant HMBS as purified: Wt (lane 1), R116W
(lane 2), K132N (lane 3), R167W (lane 4), R173W (lane 5) and V215E
(lane 6). See the main text for the interpretation of protein bands.
Expression of recombinant HMBS and mutants
To study the effect of the newly discovered missense mutations
K132N and V215E, together with R116W, R167W and R173W,
wt and mutant HMBS were expressed in E. coli and purified
with high yield (50 mg wt and mutant HMBS were obtained
from 1 l culture) and purity (>95 % pure) as seen by SDS–PAGE
(Figure 1A). All purified proteins showed distinct SDS–PAGE
bands, corresponding to approximately 44 kDa.
To analyse the enzyme–intermediate complexes the purified
enzymes were separated by native PAGE [14]. Previous reports
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on native PAGE analyses have shown an inconsistent number
of bands for wt HMBS [6,28,37]. In this work, we found four
major bands (Figure 1B), as also reported recently [37]. Vari-
ations in recombinant enzyme purification protocols may lead to
loss of enzyme–intermediate complexes [8,38]. The successive
increase in negative charge of the intermediates is a result of
increased number of PBGs, and the highest band in wt HMBS
(Figure 1B, lane 1) is thus interpreted to be the holoenzyme (E)
[37]. Following downwards, the bands have been associated with
ES (containing one PBG monomer substrate in addition to the
DPM cofactor), ES2 (two PBGs) and ES3 (three PBGs) [37].
All the mutations included in this work are expected to change
the charge of the protein at the given pH (8.3) and will give a
slightly different maximal migration for the intermediates. Ex-
cept for K132N, which revealed a similar pattern of bands as wt,
all the mutants showed differences in the distribution of bands
(Figure 1B). R116W failed to provide discrete bands, although a
weak band may be distinguished (* in lane 2; Figure 1B). Based
on the instability of this mutant (see below), and its secondary
structure content which resembles that of the wt apoenzyme [39]
(see also below), this band may represent a cofactor-free apo-
form of mutant HMBS [38]. R167W shows a more complex
pattern than wt HMBS with an additional faint band (*2 in lane 4;
Figure 1B) migrating above the E band, possibly representing a
partially formed holoenzyme (Figure 1B). Moreover, this mutant
also presents a discrete band between E and ES (*3), which is
also observed as a minor band for wt (lane 1; Figure 1B), and
might correspond to a non-identified catalytic intermediate. The
unstable R173W (lane 5, Figure 1B) migrated mainly as one
band, whereas V215E (lane 6, Figure 1B) showed two additional
bands to those observed in wt. The band denoted with *4 would
correspond to *2 for R167W, and *5 might indicate an accumu-
lation of the ES4 intermediate prior to product release. The ES4
intermediate is normally not observed [8] other than in situations
with slow or no release of the product [40]. The accumulation of
enzyme–intermediates seems to indicate some disturbance in the
elongation mechanism which is probably related to the misfold-
ing and instability of V215E (see below).
Kinetics parameters of wt HMBS and mutants
The steady-state kinetic characterization of the recombinant wt
and mutant enzymes presented here revealed significantly re-
duced (<5 %) relative activity at standard conditions for R116W,
R167W and R173W (Table 2), as expected [15,21,41]. The low
activity of R116W and R173W precluded the determination of
their kinetic parameters. On the other hand, for R167W the large
kinetic defect seems to be associated with a very high Km and
decreased Vmax (Figure 2, Table 2) as expected from an inef-
ficient elongation process, as described for the R167Q mutant
[28]. No loss in relative activity at standard conditions or change
in Vmax and Km, compared with wt HMBS, was measured for
K132N (Figure 2), indicating no apparent kinetic dysfunction.
The V215E mutation caused a 70 % loss in both activity and
Vmax; however, Km was unchanged (Figure 2, Table 2).
Table 2 Steady-state kinetic parameters of recombinant wt
HMBS and mutants
Mutation
Relative
activity* (%)
Vmax (nmol/h
per mg)†‡ Km (PBG) (μM)†
Wt 100 1261 +− 75 48 +− 5
R116W 0.5 n.a. n.a.
K132N 97 1182 +− 78 41 +− 6
R167W 4.2 615 +− 21 1579 +− 111
R173W 0.6 n.a. n.a.
V215E 30 423 +− 36 39 +− 9
*Relative activity was measured at standard conditions: wt and mutant HMBS (∼5 μg)
and 100 μM PBG for a reaction time of 4 min at 37 ◦C. The same results were obtained
after 20 min incubation.
†Vmax and Km were calculated using fitting of the data to Michaelis–Menten kinetics.
‡The activity of HMBS was defined as nmol of uroporphyrinogen I/h per mg of enzyme
at 37 ◦C under the given assay conditions.
Figure 2 The catalytic activity of wt HMBS and mutants as a
function of the substrate (PBG) concentration
Activity is measured as uroporphyrinogen I formation at 37 ◦C. Wt (,
n = 8), K132N (, n = 8), R167W (, n = 12), and V215E (, n = 10).
Conformational and thermal stability studies
To better understand the decreased activity of most of the mutants,
CD and DSF were applied to investigate the conformation and
thermal stability compared with the wt. The far-UV spectrum of
wt (Figure 3A) showed two local minima at 208 and 222 nm,
and provided a content in α-helical and β-sheet structure in ac-
cordance with the X-ray crystal structure of the human enzyme
[42,43]. The secondary structure content estimated from the far-
UV spectra is given in Table 3. Similar results were obtained for
K132N and R167W. A mild conformational defect was revealed,
however, for R173W, while the large loss of ellipticity at equal
protein concentrations observed for R116W and V215E was con-
current with largely decreased α-helical content, a feature char-
acteristic of the apoenzyme of E. coli HMBS [39]. Native PAGE
supported an unstable apoenzyme conformation for R116W [44],
whereas for V215E a putative species corresponding to the par-
tially formed holoenzyme (*4) may also be accompanying the
stable intermediates (Figure 1B). The unfolding profiles from
temperature-dependent CD shown in Figure 3(B) exhibit the loss
of ellipticity for R116W and V215E, as also seen by far-UV. Nor-
malized unfolding profiles of wt and mutants were fitted to a two-
state transition model (Figure 3C) and Tm-values were extracted,
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Figure 3 Conformational stability of wt HMBS and mutants, as studied by CD and DSF
(A) Far-UV CD of wt (), R116W (), K132N (), R167W (), R173W () and V215E (). [θ ], mean residue ellipticity.
(B) The CD-monitored thermal denaturation, presented as mdeg at 222 nm versus temperature. (C) The CD-monitored
thermal denaturation, normalized to fraction of unfolded protein, and curve fitting to a two-state transition model for wt
(1), R116W (2), K132N (3), R167W (4), R173W (5) and V215E (6). (D) Thermal denaturation monitored by DSF for wt (),
R116W (), K132N (), R167W (), R173W () and V215E (). A representative plot of each of four parallels is shown
in the figure. The Tm-values obtained from (C) and (D) are summarized in Table 4.
further revealing the large conformational instability of R116W
and R173W. For wt HMBS the Tm obtained was very high, i.e.
Tm∼74 ◦C (Table 4), as expected from the high thermal stability
of the enzyme activity [14,15,45]. R116W and R173W displayed
lower Tm-values, approx. 53 and 60 ◦C, respectively (Figure 3C,
Table 4), reflecting their lower thermal stability, whereas K132N
and R167W showed stability similar to that of wt. For the V215E
mutant, despite the decrease in ellipticity observed by CD (Fig-
ures 3A and 3B), temperature-dependent CD provided Tm similar
to wt. Further insight on this mutant, comparative to the wt and
the other mutant forms was obtained by DSF.
DSF (Figure 3D) largely confirmed the results from the CD
measurements for wt, R116W, K132N, R167W and R173W,
although the Tm-values were lower than those obtained by
temperature-dependent CD, as summarized in Table 4. Moreover,
DSF provided evidence for two unfolding transitions for wt and
all mutants, except for the most unstable R116W, and hence
gave a more detailed insight into the conformational stability of
the enzyme–intermediate components in each preparation than
temperature-dependent CD. In particular, DSF revealed a large
enzyme population with reduced stability (Tm = 43 ◦C) in V215E
(Figure 3D, Table 4). Both temperature-dependent CD and DSF
Table 3 The content of secondary structure in wt HMBS and
mutants estimated from far UV CD spectra
Secondary structure is estimated from far-UV CD spectra using the
CDNN algorithm [34].
Mutation α-helix (%) β-sheet (%)
Wt 26.7 +− 0.3 23.4 +− 0.3
Wt (X-ray)* 31.2 19.8
R116W 16.2 +− 0.1 41.9 +− 0.4
K132N 27.0 +− 0.7 24.5 +− 1.5
R167W 28.4 +− 0.3 21.8 +− 0.3
R173W 24.9 +− 0.3 26.6 +− 0.5
V215E 17.7 +− 0.2 38.3 +− 0.6
*Determined from the crystal structure of the human enzyme (PBD 3ECR) using the
DSSP algorithm [42,43].
monitor the unfolding transitions for the overall 3D structure,
where thermal CD at 222 nm follows the unfolding of the second-
ary structure, notably α-helical, and DSF displays the solvent ex-
posure of hydrophobic patches. [46]. Although the profiles from
CD and fluorescence methods are coincident for numerous pro-
teins, different thermal denaturation profiles, and consequently
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Table 4 The Tm for wt HMBS and mutants as measured by CD
and DSF
Tm-values (◦C)
Mutation CD* DSF† DSF, Tm1‡ DSF, Tm2‡
Wt 74.0 +− 0.1 71.1 +− 0.6 54.4 +− 0.8§ 72.8 +− 0.3
R116W 53.1 +− 0.4 42.6 +− 2.1 42.1 +− 1.7 -
K132N 74.1 +− 0.3 69.4 +− 0.3 53.3 +− 0.5§ 71.0 +− 0.2
R167W 74.3 +− 0.0 67.8 +− 0.2 48.2 +− 0.9§ 70.6 +− 0.1
R173W 60.3 +− 0.2 44.5 +− 0.6 45.6 +− 0.4 62.8 +− 0.1
V215E 74.5 +− 0.3 54.7 +− 2.8 43.2 +− 0.5 70.3 +− 0.4
*Determined at fraction of unfolded = 0.5 by curve fitting of the thermal transitions
[35,36]. See Figure 3(B).
†Determined at fraction of unfolded = 0.5 in the thermal transitions. See Figure 3(C).
‡Tm1 and Tm2 were calculated from the first derivative using the transitions observed in
the temperature scans. See Figure 3(D).
§Minor transitions.
Tm-values, might be obtained from these two methods, as has
often been observed [47–49]. In order to interpret the obtained
thermostability data for wt and mutants as isolated we performed
stability studies with PBG saturation (see below).
While the kinetic failure in R116W is associated with a mis-
folded enzyme unable to acquire cofactor, this is not the case for
R173W, which also includes a population of properly folded en-
zyme as supported by native PAGE, CD and DSF. Moreover, this
mutation appears to directly affect the binding of substrate and the
elongation mechanism, resulting in accumulation of mainly one
intermediate (lane 5; Figure 1B). R167W, on the other hand, is
a representative kinetic mutation [6,28], with its conformational
change having little effect on the stability of the protein.
HMBS is destabilized upon substrate saturation
The thermostability of wt and mutant HMBS was further ana-
lysed by DSF in the presence of increasing amounts of the sub-
strate PBG (Figure 4). An increase in thermodynamic stability
is usually seen upon ligand binding [50], and the binding of
the DPM cofactor to the apoenzyme triggers a conformational
change to a more compact enzyme [5,6,39]. However, when sat-
urated with 20-fold substrate (100 μM PBG) both wt HMBS and
K132N produced a shift in Tm-values (Tm = 4.5 ◦C) towards
lower temperature (Figures 4A and 4C). The decreased stabil-
ity may reflect an overall change in the equilibrium within the
intermediates, towards less stable species. A tendency towards
a more homogeneous enzyme sample was also seen, as the two
observed transitions collapse into one at the highest substrate
concentration. Heat treatment in this assay at high concentra-
tion of substrate may, however, induce a redistribution of the
enzyme–intermediate complexes because of on-going catalysis
[8]. Nevertheless, loss in stability with an increasing number of
substrates appears to be in agreement with the suggested opening
and loosening of the enzyme structure in order to accommod-
ate the hexapyrrole and to prepare for product release [6,12,13].
Neither R116W nor R173W were affected by the addition of,
and saturation with, PBG (Figures 4B and 4E), a fact supported
by the kinetic analyses. These results agree with previous reports
on the lack of proper cofactor or substrate binding and depleted
Figure 4 Thermal stability of wt HMBS and mutants with increasing concentration of PBG
0 μM (solid line), 1 μM (·····), 25 μM (- - -), 50 μM (··-··) or 100 μM (– –) PBG was added to 2 μM wt HMBS or mutants.
For R167W, addition of 500 μM () and 1000 μM () PBG were also analysed. (A) For wt HMBS, a Tm − 4.5 ◦C was
measured at saturating concentration of PBG. (B) R116W, Tm∼0 ◦C. (C) K132N, Tm∼ − 4.5◦. (D) R167W, Tm∼0 ◦C
(1–100 μM PBG). 500 and 1000 μM PBG gave Tm∼ − 1.5 ◦C and − 4 ◦C, respectively. (E) R173W Tm∼0 ◦C. (F) V215E
was the mutant most affected upon titration with PBG. The first transition (arrow) was clearly stabilized (Tm∼14 ◦C) upon
saturation with PBG, whereas the second transition was only slightly destabilized (Tm∼ − 2 ◦C).
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Figure 5 DSF of the fractionated peaks obtained from ion-
exchange chromatography of wt HMBS and the V215E mutant
(A) For wt HMBS, the unfolding transitions show decreasing thermal
stability with increasing retention time, indicating that the stability is
decreased with increasing amount of bound PBG-molecules (E, peak 1;
ES, peak 2; ES2, peak 3; ES3, peak 4). Tm is∼ − 5 ◦C from peak 1
to peak 4. The inset shows the ion-exchange chromatography profile.
(B) For V215E, the ion-exchange chromatography profile shows a rather
similar pattern to that of wt, but further investigation with DSF reveals
a wider span of thermal stability (Tm = − 18.5 ◦C) for the fractions
obtained for this mutant.
activity of mutants with substitutions at Arg116 [15,26] and Arg173
[4,21]. R167W only revealed a decrease in Tm when incubated
with high PBG concentrations (500 and 1000 μM) (Figure 4D),
in agreement with the high Km-value, indicative of a low affin-
ity for the substrate (Table 2). V215E, however, showed a rather
different denaturation profile with a noticeable change in distri-
bution with increasing PBG concentration (Figure 4F) where the
transition with the lowest stability was shifted towards higher
Tm. The most stable population (close to wt in Tm, see Table 4)
was less affected. Higher PBG-concentrations (up to 4 mM, res-
ults not shown) did not further affect the denaturation profiles or
V215E activity in agreement with a wt-like Km (Table 2) indicat-
ing that the folding defect is the main contributor to the impaired
mechanism of this mutant.
The four bands observed in native PAGE for the purified wt
HMBS (lane 1; Figure 1B) were fractionated by anion-exchange
chromatography. In addition, we investigated the thermal denat-
uration of each fractionated peak by DSF. Initially, each peak
was analysed by native PAGE (results not shown) and correlated
to the major species in Figure 1(B), being E (holoenzyme, peak
1), ES (peak 2), ES2 (peak 3) and ES3 (peak 4) (Figure 5A),
as previously reported [37]. The thermal stability of the inter-
mediate complexes revealed that increasing amounts of bound
substrate decreased the overall thermal stability of wt HMBS
(Figure 5A). Analysis of K132N provided similar results to wt
(results not shown) whereas V215E displayed a much larger shift
between the peaks with the shortest and the longest retention
times (Tm = − 18.5 ◦C) (Figure 5B). This is in agreement with
the complex DSF profile for the unfractionated preparation (Fig-
ures 3D and 4F). Nevertheless, most of the less stable population
seen by DSF (Figure 3D), which probably correspond to the frac-
tion *4 (lane 6, Figure 1B), is not observed in the fractions, and
was most likely lost through aggregation and interaction with
the chromatographic material during anion-exchange chromato-
graphy.
Conclusion
In this work, we have acquired knowledge on the conforma-
tional stability of wt HMBS and selected mutants, as well as
gained insight into the elongation process of the HMBS cata-
lysis. The results also contribute to the understanding of the
phenotype-genotype correlations in AIP. R116W and R173W,
the two mutants with the most severe phenotype, present an al-
most total kinetic dysfunction which is largely associated with
their severe conformational instability. R167W presents a less
severe phenotype yet high association with AIP, and the clinical
profile is mainly associated with a catalytic disruption. The novel
mutation investigated in this work, K132N, has an unclear clinical
significance, and our results show similar kinetic, conformational
and thermal stability to wt HMBS, supporting that this mutation
does not induce or cause classical AIP symptoms or biochemical
findings. Lys132 is localized on the surface of domain 2, away
from the active site, and is most likely not directly involved in the
synthesis of HMB. The previously reported, although uncharac-
terized, V215E is located in the vicinity of the active site, and is
part of a hinge region connecting domains 1 and 2. Although not
interacting directly with the cofactor, the substitution of a hydro-
phobic Val with a negatively charged Glu residue in this position
appears to alter intramolecular interactions, affecting the folding
and stability of the enzyme, and the faulty mechanism of V215E
appears to be the result of the folding defects. There seems to
be a close relationship between the biochemical characteristics
of the isolated recombinant enzyme, the biochemical phenotype,
and the AIP association. The patients are highly affected, with
59 % experiencing attacks, and our findings correlate with the
high disease association.
Our results contribute to increasing our knowledge and un-
derstanding of the complete biochemical mechanism and the
molecular basis for the phenotypic outcome of HMBS mutants,
which is important in the future investigation of treatments for
AIP.
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Figure S1 Structural model of HMBS
The location of the two novel mutations studied in this work, K132N and
V215E, are presented as ball-and-sticks in red, whereas the three pre-
viously reported mutations (R116W, R167W and R173W) are presen-
ted as ball-and-sticks in dark blue. The complete structural model of
HMBS was constructed with Modeller [1] based on multiple templates
(PBD IDs: 1AH5, 1PDA, 1GTK, 1YPN, 3ECR and 3EQ1). Coordinates for
residues 55–75 have been issued to loop optimization constructing a
large set of possible confirmations. The lowest energy structure was
chosen, and further refined with energy minimization using Amber 10
[2].
1 To whom correspondence should be addressed (email helenejbustad@gmail.com).
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